Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris (NCT03662685) | Clinical Trial Compass
TerminatedPhase 1
Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris
Stopped: Closing of the Goeckerman program at UCSF and loss of funding, PI left UCSF
United States4 participantsStarted 2018-08-01
Plain-language summary
This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Male or female ≥ 18 years of age at enrollment.
. Documentation of predominately moderate to severe plaque psoriasis for at least 6 months prior to enrollment.
. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.
. Subject is considered a candidate for phototherapy or systemic therapy
. Body Surface Area (BSA) ≥ 5%.
. Physical exam within clinically acceptable limits.
Exclusion criteria
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of differentially expressed immune cell populations
. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
. Subject has predominantly non-plaque form of psoriasis.
. Subject has drug-induced psoriasis.
. Subject with current, or a history of, severe psoriatic arthritis well controlled on current therapy.
. Patient has absolute or relative contraindication to phototherapy, including photosensitizing disorders.
. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.
. Known HIV positive status.
. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents.